The new event BioLive will create unique synergies between the parallel worlds of large, small molecules and contract services. It will be held next year in Madrid.
UBM ’s pharma portfolio recently announced the launch of a new bespoke and independently branded biopharma event, BioLive, will be held next year in Madrid. The event will focus on bio processing and manufacturing and will take place from October 9-11, 2018 at IFEMA, Feria de Madrid.
The new event has been created after independent research identified a gap in the market for a new global exhibition and content platform that could establish premium-class, global leadership across the entire bio manufacturing value chain.
Focus at the show: connecting biotechs
BioLive will serve as a global hub for both upstream and downstream processing and manufacturing, connecting biotechs, big pharma and service providers including CDMOs and CROs from early stage development to commercial manufacturing and regulatory services. It will also feature bio generic and bio innovator audiences through to manufacturing and laboratory specialists.
Analyst research indicated that running the new event in parallel to its enormous contract services (ICSE) and small molecule (CPhI Worldwide) exhibitions – both currently the world’s largest in their respective areas – would create natural synergies and establish the first truly global hub covering the entire biopharma and pharma supply chains.